Tag Archives: hepatitis c

November, 2018

September, 2018

October, 2017

September, 2017

  • 29 September

    Merck Discontinues MK-3682B and MK-3682C Development Programs

    KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced its strategic decision to discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/ uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. This decision was made based on …

August, 2017

July, 2017

April, 2017